首页> 外国专利> Detecting primate T cell lymphoma/leukemia viruses, useful e.g. for diagnosis and drug screening, using degenerate oligonucleotides based on conserved regions of envelope protein

Detecting primate T cell lymphoma/leukemia viruses, useful e.g. for diagnosis and drug screening, using degenerate oligonucleotides based on conserved regions of envelope protein

机译:检测灵长类T细胞淋巴瘤/白血病病毒,例如使用基于包膜蛋白保守区的简并寡核苷酸进行诊断和药物筛选

摘要

Use of a pair of 5'- and 3'-oriented degenerate oligonucleotides (dON) for detecting any strain, including new strains, of primate T cell lymphoma/leukemia viruses (PTLV) or related viruses, is new. dON are derived from sequences that encode the N-terminal region of the surface component (SU) of the viral envelope protein. Use of a pair of 5'- and 3'-oriented degenerate oligonucleotides (dON) for detecting any strain, including new strains, of primate T cell lymphoma/leukemia viruses (PTLV) or related viruses. dON are derived from sequences that encode the N-terminal region of the surface component (SU) of the viral envelope protein, i.e. the region extending from amino acid (aa) 75-90 (N-terminal) to 230-245 (C-terminal). The virus is derived from human (H) or simian (S) T-cell lymphotropic viruses (TLV) strains HTLV-1 or -2 or STLV-1, -2 or -3, or related viruses in which the aa sequence, deduced from nucleic acid coding sequences for the N-terminus of SU, is at least 30% homologous. Detection comprises: (i) amplification using dON as primers; and (ii) identification of the strain from the resulting amplicon. Independent claims are also included for: (1) dON as new compounds; (2) process for detecting PTLV using dON; (3) kit for detecting the specified viruses comprising a pair of dON as primers and optionally reagents for performing PCR and detecting amplicons; (4) HTIV-1 and -2 variants obtained by the new process; (5) polypeptide (I) defined by aa 75-90 (N-terminus) and 230-245 or 135-150 (C-terminus) of PTLV; (6) nucleic acid (II) that encodes (I); (7) mono- and poly-clonal antibodies (Ab) directed against the variants of (4) or (I); and (8) pharmaceutical composition, particularly vaccines or therapeutic vectors, containing (I), (II) or Ab.
机译:使用一对5'和3'定向简并寡核苷酸(dON)检测灵长类T细胞淋巴瘤/白血病病毒(PTLV)或相关病毒的任何菌株,包括新菌株。 dON源自编码病毒包膜蛋白表面成分(SU)N端区域的序列。一对5'和3'定向的简并寡核苷酸(dON)用于检测灵长类T细胞淋巴瘤/白血病病毒(PTLV)或相关病毒的任何菌株,包括新菌株。 dON源自编码病毒包膜蛋白表面成分(SU)N端区域的序列,即从氨基酸(aa)75-90(N端)延伸至230-245(C-终奌站)。该病毒衍生自人(H)或猿猴(S)T细胞淋巴病毒(TLV)株HTLV-1或-2或STLV-1,-2或-3或相关的病毒,其中推导了aa序列与SU的N端的核酸编码序列的同源性至少为30%同源。检测包括:(i)使用dON作为引物进行扩增; (ii)从所得的扩增子中鉴定菌株。还包括以下方面的独立权利要求:(1)dON作为新化合物; (2)使用dON检测PTLV的过程; (3)用于检测特定病毒的试剂盒,其包含一对dON作为引物,以及任选地用于进行PCR和检测扩增子的试剂。 (4)通过新方法获得的HTIV-1和-2变体; (5)由PTLV的aa 75-90(N末端)和230-245或135-150(C末端)定义的多肽(I); (6)编码(I)的核酸(II); (7)针对(4)或(I)的变体的单克隆和多克隆抗体(Ab); (8)含有(I),(II)或Ab的药物组合物,特别是疫苗或治疗载体。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号